Dr. Tanner M Johanns, M.D., Ph.D.
Claim this profileWashington University School of Medicine
Studies Glioblastoma
Studies Brain Tumor
24 reported clinical trials
40 drugs studied
Area of expertise
1Glioblastoma
IDH negative
Stage IV
germline
2Brain Tumor
IDH positive
1p/19q co-deletion positive
IDH negative
Affiliated Hospitals
Clinical Trials Tanner M Johanns, M.D., Ph.D. is currently running
Personalized DNA Vaccine + PD-1 Blockade
for Glioblastoma
This is a single institution, open-label, multi-arm, phase I study assessing the safety and immunogenicity of a personalized neoantigen-based personalized DNA vaccine combined with PD-1 blockade therapy in subjects with newly diagnosed, MGMT promoter unmethylated glioblastoma (GBM). Immune checkpoint blockade, specifically those targeting the PD-1/PD-L1 pathways, has shown efficacy in multiple solid and hematologic malignancies. Furthermore, as has been demonstrated in metastatic melanoma, combining PD-1/PD-L1 blockade with other immune checkpoint inhibitors has shown improved objective response rates, though there is a significant increase in serious immune-related adverse events. As such, current trials are exploring different doses, administration schedules, and immune checkpoint agents. One alternative approach, however, is to introduce a tumor-directed therapy such as a personalized neoantigen vaccine combined with these immune modulating agents (i.e. immune checkpoint blocking antibodies) to maximize the tumor-specific response but minimize the toxicity associated with increasing non-specific systemic immune activation by generating a potent and focused neoantigen specific immune response. This study will test the hypothesis that a personalized neoantigen DNA vaccine in combination with concurrent administration of immune checkpoint blockade therapy will enhance the magnitude and breadth of neoantigen-specific T cell responses while maintaining an acceptable safety profile. The overall goal of this study is to identify the optimal vaccine plus adjuvant platform that can be tested in a subsequent phase II study to determine the efficacy of a personalized neoantigen vaccine approach in patients with GBM.
Recruiting1 award Phase 1
Nivolumab
for Cancer
This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Recruiting1 award Phase 120 criteria
More about Tanner M Johanns, M.D., Ph.D.
Clinical Trial Related3 years of experience running clinical trials · Led 24 trials as a Principal Investigator · 7 Active Clinical TrialsTreatments Tanner M Johanns, M.D., Ph.D. has experience with
- Nivolumab
- Retifanlimab
- Pembrolizumab
- Ipilimumab
- Personalized Neoantigen DNA Vaccine
- Surgery
Breakdown of trials Tanner M Johanns, M.D., Ph.D. has run
Glioblastoma
Brain Tumor
Melanoma
Protoplasmic Astrocytoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Tanner M Johanns, M.D., Ph.D. specialize in?
Tanner M Johanns, M.D., Ph.D. focuses on Glioblastoma and Brain Tumor. In particular, much of their work with Glioblastoma has involved IDH negative patients, or patients who are Stage IV.
Is Tanner M Johanns, M.D., Ph.D. currently recruiting for clinical trials?
Yes, Tanner M Johanns, M.D., Ph.D. is currently recruiting for 7 clinical trials in Saint Louis Missouri. If you're interested in participating, you should apply.
Are there any treatments that Tanner M Johanns, M.D., Ph.D. has studied deeply?
Yes, Tanner M Johanns, M.D., Ph.D. has studied treatments such as Nivolumab, Retifanlimab, Pembrolizumab.
What is the best way to schedule an appointment with Tanner M Johanns, M.D., Ph.D.?
Apply for one of the trials that Tanner M Johanns, M.D., Ph.D. is conducting.
What is the office address of Tanner M Johanns, M.D., Ph.D.?
The office of Tanner M Johanns, M.D., Ph.D. is located at: Washington University School of Medicine, Saint Louis, Missouri 63110 United States. This is the address for their practice at the Washington University School of Medicine.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.